Bicara Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Bicara Therapeutics is a clinical-stage biotechnology company developing bifunctional antibodies designed to modulate tumors directly at the site of disease. Based in Boston, Massachusetts, and founded in 2020, the company is advancing its lead candidate, ficerafusp alfa (FICERA), a potentially first-in-class bifunctional antibody that pairs an EGFR-targeting component with a TGF-β ligand trap. The design aims to localize tumor targeting and deliver a modulating signal to counteract fibrosis, immunosuppression, and TGF-β–driven resistance within solid tumors.

The company operates in the biotechnology research industry and pursues improvements in immune cell penetration and durability of responses in cancer therapy. In January 2025, Bicara presented Phase 1/1b dose-expansion results with Ficerafusp Alfa in advanced squamous cancer of the anal canal at the ASCO Gastrointestinal Cancers Symposium.

Get verified Bicara Therapeutics emails free

Company overview Employee directory